Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hammerschlag, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hammerschlag, M. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 48, 735
© 2001 The British Society for Antimicrobial Chemotherapy

Correspondence

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin

Margaret R. Hammerschlag,*

SUNY Downstate Medical Center, Brooklyn, NY 11203-2098, USA

Sir,

File et al.1 reported eradication rates for Mycoplasma pneumoniae of 93% for gemifloxacin and 95% for trovafloxacin, although the diagnosis . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
D. W. Hecht and J. R. Osmolski
Activities of Garenoxacin (BMS-284756) and Other Agents against Anaerobic Clinical Isolates
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 910 - 916.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
X. Zhao, W. Eisner, N. Perl-Rosenthal, B. Kreiswirth, and K. Drlica
Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1023 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. Ince, X. Zhang, L. C. Silver, and D. C. Hooper
Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone
Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3370 - 3380.
[Abstract] [Full Text] [PDF]